Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imipenem

The gold standard of scientific evidence

Will randomised controlled trials become a thing of the past?

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

Patient recruitment and engagement standards

Clinical trial awareness

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

Janssen develops digital tools to help automate clinical trials

iSTEP platform combines mobile tech and smart packaging

- PMLiVE

CETP inhibitor class finally dies as Merck abandons anacetrapib

Cholesterol drug fails to “support regulatory filings”

Can Cinderella save us?

Motif Bio preps US filing after antibiotic clears phase III

The UK biopharma hopes to launch iclaprim by early 2019

- PMLiVE

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links